Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter


Zacks on Access Pharmaceuticals: MuGard sales continued to grow in 1Q12 and will keep current momentum; Outperform (ACCP)

Access Pharmaceuticals (ACCP) is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one FDA-approved product, two products in Phase II clinical development, three products in preclinical development. Several of the company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.

Zacks.com has released a report on Access Pharmaceuticals entitled "MuGard sales continued to grow in 1Q12 and will keep current momentum." Zacks maintains an "Outperform" rating on ACCP but lowers the price target. 

Purchase the report online at AlacraStore.com

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Binghamton University S3IP Center and Applied DNA Sciences Partner on DNA Authenticity Technologies for Microelectronics (APDN) | Main | UPDATE: New Speaker at "The Age Of 'Big Data' In Bioscience Is Here, But Are We Prepared For It?" Panel Discussion in NYC on June 7, 2012 »